Com.P.li.t DX Colon is a multi-gene assay for the individualization of the treatment plan of patients' with colon cancer.

Com.Pl.i.t DX
Colon


Com.Pl.i.t DX Colon is a multigene test designed to help you and your physician make informed treatment decisions based on the unique biology of your tumor and individualize your treatment.

ORDER COMPLIT DX-COLON

Who should be tested?

Com.Pl.i.t DX Colon is designed in order to allow you and your physician to select which is the optimal treatment for your diagnosis based on the biology of your tumor.

Who should be tested?

Different Com.Pl.i.t DX Colon panels are designed for Colorectal Cancer patients.

The test includes the following genes:

 27 Gene Alterations

AKT1

ALK

BRAF

CDKN2A

CTNNB1

DDR2

EGFR

ERBB2

FBXW7

FGFR1

FGFR2

FGFR3

HRAS

KEAP

KRAS

MAP2K1

MET*

NOTCH1

NRAS

PIK3CA

POLE

PTEN

RET

SMAD4

SMARCA4

STK11

TP53

 

 

 

* MET amplification and MET exon 14 skipping are also included in the analysis

     

 

7 fusion transcripts

ALK ROS1 RET NTRK1 NTRK2 NTRK3 MET

 

Immunotherapy Biomarkers

  MSI

 

Clinical Utility

The Com.Pl.i.t DX Colon assay provides valuable information that can be utilized for selecting the optimal targeted treatment for patients. By analyzing many genes at the same time it provides a detailed blueprint of the biology of the tumor, which is used by the treating physician to individualize the patient’s treatment plan.
Com.Pl.i.t DX Colon is designed to help physicians select targeted treatments for their patients and avoid the toxicity and other side effects of chemotherapy which has been already used with limited response and in some cases even resistance.

What you get

Report

An individualized report that summarizes the findings of the biology of your tumor is provided to you and your physician.

Support

Genekor takes care of all the logistics in order for your sample to arrive to our laboratory safely.

Interpretation

Our team of experts is here to interpret your results to you and your treating physician.

FAQS

Result Information

Possible Outcomes

On the Genomic Alterations Section a more detailed interpretation about the Genomic Alterations identified is contained, including frequencing ratios, biological impact and related targeted therapies.

On the Clinical Trials Section all the currently available clinical trials are reported according to the molecular profile of the patient’s tumor.

Furthermore, details about the methodology of the assay are reported on the Methodology Section.

How to get Started

1

Order the test

Ask your physician if you are eligible for the Com.Pl.i.t DX Colon test.

2

Sample requirements

Tissue from surgery or biopsy which is embedded in paraffin (FFPET) is required for this test. Your sample will be collected per your physicans' instructions.

3

Analysis Process

Your sample will arrive to our accredited laboratory and your report will be generated and sent to you and your physician in 10 working days.

4

Reporting

Your report will be electronically released to your physician via email and/or uploaded to our secure portal, and to you via email or mail.

Technical Info

Com.Pl.i.t DX is designed in order to achieve maximum sensitivity and specificity. All findings are classified using the most reliable and updated databases and in silico analysis algorithms.
Advanced Next Generation Sequencing technology, also known as NGS, is used to fully analyze a panel of genes that are related to targeted treatments. Analysis of gene fusions is also included in Com.Pl.i.t DX, providing comprehensive and reliable information to patients and physicians.

 

For more scientific and technical information you can contact us: scientific.support@genekor.com

 

Change cookies consent Revoke cookies consent